SEC Charges Ex-FibroGen Chief Medical Officer for False & Misleading Claims About Clinical Trial Results
September 11, 2025
September 11, 2025
WASHINGTON, Sept. 11 -- The Securities and Exchange Commission issued the following litigation release (No. 3:25-cv-07593; N.D. Cal. filed Sept. 5, 2025) involving Kin-Hung Peony Yu:
* * *
On September 5, 2025, the Securities and Exchange Commission filed charges against Dr. Kin-Hung Peony Yu, the former Chief Medical Officer of FibroGen, Inc., for allegedly making false and misleading statements about the cardiovascular safety of FibroGen's then-primary drug candi . . .
* * *
On September 5, 2025, the Securities and Exchange Commission filed charges against Dr. Kin-Hung Peony Yu, the former Chief Medical Officer of FibroGen, Inc., for allegedly making false and misleading statements about the cardiovascular safety of FibroGen's then-primary drug candi . . .